Zhongyianke Biotech
Tianjin
About Zhongyianke Biotech
Zhongyianke has launched a flu vaccine and is conducting clinical trials on four other human vaccines: a tetravalent influenza vaccine, a tetravalent meningococcal vaccine, a rabies vaccine, and a rubella vaccine. The company holds 14 China patents. In addition to its operations in Tianjin, the company has an R&D center in Beijing and a production facility in Liaoning Province.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $36.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2020)
- Website: gazobiotech.com
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/zhongyianke-biotech-133895 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.